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Background: miRNAs are non-coding RNAs that regulate gene expression in a wide range of biological contexts,
including a variety of diseases. The present study clarified the role of miR-214-5p in hepatic fibrogenesis using
human clinical tissue samples, livers from rodent models, and cultured hepatic stellate cells.
Methods: The expression of miR-214-5p and genes that are involved in liver fibrosis were analyzed in hepatitis C
virus-infected human livers, rodent fibrotic livers, a human stellate cell line (LX-2), and the cells from intact mouse
livers using real-time PCR. The effect of miR-214-5p overexpression in LX-2 cells on cell function was investigated.
Twist-1 expression in the liver tissues of mouse models and primary-cultured stellate cells was also analyzed.
Results: miR-214-5p was upregulated in human and mouse livers in a fibrosis progression–dependent manner.
miR-214-5p expression increased during the culture-dependent activation of mouse primary stellate cells and was
significantly higher in stellate cells than in hepatocytes. The overexpression of miR-214-5p in LX-2 cells increased
the expression of fibrosis-related genes, such as matrix metalloproteinase (MMP)-2, MMP-9, α-smooth muscle actin,
and transforming growth factor (TGF)-β1. TGF-β stimulation induced miR-214-5p in LX-2 cells. Twist-1 was increased
in fibrotic mouse livers and induced during mouse stellate cell activation.
Conclusion: miR-214-5p may play crucial roles in the activation of stellate cells and the progression of liver fibrosis.
Twist-1 may regulate miR-214-5p expression in the liver, particularly in stellate cells.
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Liver fibrosis is a consequence of chronic liver trauma
caused by hepatitis B or hepatitis C virus (HCV) infection,
alcohol abuse, or steatohepatitis, which ultimately leads to
liver cirrhosis, liver failure, and hepatocellular carcinoma
[1]. Liver fibrosis is characterized by an abnormal accumu-
lation of extracellular matrix (ECM) components, includ-
ing types I and III collagen, laminin, and proteoglycans, in
the liver parenchyma [2,3]. Transforming growth factor
(TGF)-β, which is produced and released by activated
macrophages and platelets at the site of local inflamma-
tion, is considered to play a primary role in the fibrotic
process [3]. Hepatic stellate cells - which are localized in* Correspondence: kawadanori@med.osaka-cu.ac.jp
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reproduction in any medium, provided the orDisse’s space, store vitamin A and act as tissue-specific
pericytes under physiological conditions - undergo activa-
tion and transformation into myofibroblast-like cells that
express α-smooth muscle actin (α-SMA) during persistent
inflammation. The activated stellate cells become an add-
itional source of TGF-β and a principal producer of ECM
components. However, the detailed molecular mechan-
isms of TGF-β production in these cells have not been
determined [4].
miRNAs are 20 to 24 nucleotide non-coding RNAs
that are involved in the post-transcriptional regulation
of gene expression. Mature miRNAs are incorporated
into an RNA-induced silencing complex that recognizes
target mRNAs through imperfect base pairing with the
miRNA. This action triggers the translational inhibition or
destabilization of the target mRNA, which results in the
regulation of crucial biological processes, such as develop-
ment, differentiation, apoptosis and cellular proliferationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 miR-214-5p expression in the livers of patients with chronic hepatitis C virus infection. miR-214-5p expression in the livers of 35
hepatitis C virus (HCV)-infected patients was analyzed using real-time PCR. (A) Representative sirius red staining of liver tissues with fibrosis stages
F1-F4 of chronic hepatitis C patients included in this study. (B) miR-214-5p expression in samples from each stage of liver fibrosis (METAVIR
scoring system). The numbers of patients in each stage were: F1, 17; F2, 8; F3, 8; and F4, 2. The Jonckheere-Terpstra test identified trends among
classes. (C) Comparison of miR-214-5p expression in F1/F2 and F3/F4 samples. (D) Comparison of miR-214-5p expression between F1 and F2-4.
The levels of miR-214-5p expression in B, C and D are indicated relative to F1, F1/F2 and F1, respectively. *P< 0.05.
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with a variety of diseases, including proliferative vascular
disease [7], cardiac disorders [8,9], polycystic kidney dis-
ease [10], and cancer [11,12]. Several miRNAs can be used
as biomarkers for cancer [13,14] because miRNA expres-
sion patterns in human cancer are tissue specific [15].
miR-122 is the most abundant miRNA in the liver,
where it regulates fat metabolism and the replication of
HCV in hepatocytes and contributes to carcinogenesis
[16,17]. miR-122 has been used as a novel biomarker for
liver damage in rat models of hepatocellular injury caused
by a methionine- and choline-deficient diet (MCDD),
CCl4 or acetaminophen and bile duct ligation [18]. We
previously reported that miR-29b regulates collagen ex-
pression by binding to the 3′-UTR of the type 1 collagen
alpha 1 chain (Col1a1) and SP1 mRNAs [19], and miR-
29b directly inhibits the activation of mouse stellate cells
in primary culture [20]. It was recently reported that miR-
19b suppresses the activation of stellate cells via the inhib-
ition of TGF-β signaling by interacting with the type II
TGF-β receptor [21].miR-214-5p is a product of the 110 bp miR-214 gene in
the intron of the Dynamin-3 gene on human Chromosome
1-NC_000001.10, which produces a mature miRNA with a
sequence of ugccugucuacacuugcugugc [22]. TGF-β induces
miR-214 expression in rat tubular epithelial cells and
mesangial cells [23], and miR-214 interacts with Quaking
to inhibit angiogenesis [24]. However, the pathophysio-
logical roles of miR-214 remain largely unknown. Here,
we report the upregulation of miR-214-5p in a fibrosis
progression–dependent manner in HCV-infected human
livers and in the livers of a rodent fibrosis model.
The role of miR-214-5p in hepatic stellate cell activa-
tion is also discussed.
Results
miR-214 expression in chronic hepatitis C patients
We previously found that, using microRNA array ana-
lysis, miR-221/222 expression was upregulated in a fi-
brosis progression–dependent manner in human livers that
are chronically infected with HCV [25]. In addition, we
quantitatively confirmed the miR-214-5p expression
AB
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Figure 2 miR-214-5p expression in mouse livers with fibrosis induced by an methionine- and choline-deficient diet. (A) Sirius red
staining (left and middle panels) and α-smooth muscle actin (SMA) immunostaining (right panels) of mouse liver tissues. Collagen deposition and
an increase in α-SMA-positive cells were evident around the central vein area of the liver of mice that received the MCDD for 15 weeks. Scale
bars, 100 μm (left and middle panels) and 200 μm (right panels). P, portal vein. C, central vein. (B) The mRNA expression of α-smooth muscle
actin (α-SMA), the type 1 collagen alpha 1 chain (Col1a1), platelet-derived growth factor receptor (PDGFR)-β, transforming growth factor (TGF)-β1,
fibronectin (FN)1, discoidin domain receptor (DDR)2, and β1 integrin (ITGB1) in fibrotic mouse livers was analyzed using real-time PCR. The results
are expressed relative to mRNA expression at 5 weeks of the methionine- and choline-control diet (MCCD). *P< 0.05. **P< 0.01. (C) miR-214-5p
expression in fibrotic mouse livers was analyzed using real-time PCR. The results are expressed relative to the expression of miR-214-5p at 5
weeks of the MCCD. *P<0.05. **P< 0.01.
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liver fibrosis (Figure 1A) using real-time PCR. We
found that miR-214-5p expression increased accord-
ing to the stage of fibrosis (P = 0.000108) (Figure 1B)and was significantly higher in patients with advanced
liver fibrosis than in those with mild fibrosis (F1/F2 ver-
sus F3/F4: 3.2-fold, P < 0.05; F1 versus F2-4: 3.1-fold,


















Figure 3 miR-214-5p expression in rat livers with fibrosis
induced by a methionine- and choline-deficient diet.
Expression of miR-214-5p in methionine- and choline-deficient
diet (MCDD)-induced liver fibrosis and recovery phase in rats.
The results are expressed relative to the expression of miR-214-5p in
the livers of rats fed the methionine- and choline-control diet (MCCD)
for 10 weeks. MCCD; rats fed MCCD for 10 weeks. MCDD; rats fed
MCDD for 10 weeks. Recover; rats fed MCDD for 8 weeks followed by
MCCD for 2 weeks. **P<0.01.
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Liver fibrosis was induced by feeding mice a MCDD
for 5 or 15 weeks and then compared with mice fed a
methionine- and choline-control diet (MCCD). Sirius red
staining and α-SMA immunostaining confirmed the time-
dependent induction of fibrosis in the liver of MCDD-fed
mice, especially around the central vein area (Figure 2A).
The mRNAs of liver fibrosis factors, such as α-SMA,
Col1a1, platelet-derived growth factor receptor (PDGFR)-β,
TGF-β1, fibronectin (FN) 1, discoidin domain receptor
(DDR) 2, and β1 integrin (ITGB1), were upregulated in
the livers of MCDD-fed mice compared to MCCD-fed
mice (Figure 2B). miR-214-5p expression was significantly
higher in the livers of MCDD-fed mice than in control
mice (2.1-fold, P< 0.01 at 5 weeks; and 4.8-fold, P< 0.01 at
15 weeks) (Figure 2C).
miR-214 expression in a rat resolution model of
liver fibrosis
We previously demonstrated the resolution of liver fibro-
sis with steatohepatitis in a rat model induced by giving
MCDD; that is, rats received either MCCD for 10 weeks,
MCDD for 10 weeks, or MCDD for 8 weeks followed by
MCCD for the last 2 weeks (the last of the these being the
recovery group) [26]. miR-214-5p expression was signifi-
cantly greater in the livers of rats that received MCDD for
10 weeks than in those that received MCCD for 10 weeks.
However, these levels returned to control levels in the
livers of rats that received the MCDD diet for 8 weeks fol-
lowed by the MCCD diet for 2 weeks, consistent with re-
covery from the fibrosis (Figure 3). These results clearly
suggest a close correlation between miR-214-5p expres-
sion in the liver, fibrosis development, and fibrosis-related
mRNA expression.
miR-214-5p expression in hepatic stellate cells
We assessed the contribution of activated hepatic stellate
cells to the increase in miR-214-5p in fibrotic mouse
livers. miR-214-5p expression increased during the culture-
dependent activation process in mouse stellate cells (2.7-
fold increase at day 7 compared to day 1, P < 0.05)
(Figure 4A). As expected, the induction of miR-214-5p
was accompanied by an increase in the expression of
α-SMA, Col1a1, PDGFR-β, and FN1 mRNA (Figure 4B).
In addition, miR-214-5p expression was markedly higher
in LX-2, a widely used human hepatic stellate cell line,
than in human liver cancer cell lines such as HepG2 and
Huh7 (108- and 39-fold, respectively) (Figure 4C).
We next isolated individual hepatocytes, non-paren
chymal cells, and hepatic stellate cells from intact mouse
livers to verify the cellular source of miR-214-5p. miR-
214-5p was localized to non-parenchymal cells and hep-
atic stellate cells but expressed at negligible levels in
hepatocytes (Figure 4D). These results suggest that miR-214 induction in fibrotic livers reflects the number and
activation status of hepatic stellate cells.
The effect of miR-214 overexpression on gene expression
in stellate cells
We investigated the effect of miR-214-5p overexpres-
sion on fibrosis-related gene expression in stellate cells to
clarify the role of this miRNA in stellate cell activation.
miR-214-5p was overexpressed in LX-2 cells by transfec-
tion with an miR-214 precursor. The overexpression of
miR-214 significantly increased the expression of matrix
metalloproteinase-2 (MMP-2), MMP-9, α-SMA, and
TGF-β1 compared to cells transfected with control micro-
RNA (1.7-, 2.8-, 1.7- and 2.0-fold, respectively; P< 0.01)
(Figure 5). These results indicate the strong participation
of miR-214 in the activation of stellate cells.
Induction of miR-214 expression by TGF-β1
TGF-β1 induces miR-214 expression in rat tubular epi-
thelial cells and mesangial cells [23]. TGF-β1 is essential
for hepatic stellate cell activation. We assessed the
stimulatory effect of TGF-β on miR-214-5p expression in
LX-2 cells. TGF-β1 (3 and 10 ng/ml) significantly stimu-
lated miR-214-5p expression in LX-2 cells after 24 hours
(1.75-fold, P< 0.05)(Figure 6A). In contrast, the expression
of the miR-214/199a cluster is controlled by the transcrip-
tion factor Twist-1 [22]. Real-time PCR analysis revealed
that Twist-1 expression increased in the livers of mice that
received MCDD compared to those of MCCD-fed mice
A B
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Figure 4 miR-214-5p expression in liver cells, including stellate cells. (A) miR-214-5p expression in mouse stellate cells during primary
culture was analyzed using real-time PCR. Stellate cells were isolated from mouse livers and cultured for 1, 4 or 7 days. The results are expressed
relative to the expression of miR-214-5p at day 1. *P< 0.05. (B) The expression of α- smooth muscle actin (α-SMA), the type 1 collagen alpha 1
chain (Col1a1), platelet-derived growth factor receptor (PDGFR)-β, fibronectin (FN)1 and transforming growth factor (TGF)-β1 mRNA in primary-cultured
mouse stellate cells was analyzed using real-time PCR. The results are expressed relative to the expression of the same mRNA at day 1. **P<0.01.
(C) miR-214-5p expression in HepG2, Huh7 and LX-2 cells was analyzed using real-time PCR. The results are expressed relative to the expression of
miR-214-5p in HepG2. **P<0.01. (D) miR-214-5p expression in hepatocytes (Hc), the non-parenchymal cell (NPC) fraction, and the hepatic stellate cell
(HSC) fraction. The cells were isolated from intact mouse livers. The miR-214-5p expression in Hc, the NPC fraction, and the HSC fraction was analyzed
using real-time PCR. The results are expressed relative to the expression of miR-214-5p in hepatocytes. **P<0.01.
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P< 0.05) (Figure 6B). Twist-1 mRNA expression was also
induced in a time-dependent manner after culture initi-
ation in primary-cultured mouse stellate cells (Figure 6C).
Discussion
This is the first report to show that miR-214-5p is involved
in organ fibrogenesis, specifically in the liver. miR-214 has
previously been predicted to be a key molecule in prolifera-
tion in breast [27] and ovarian cancer cells [28], tumor pro-
gression in melanoma [29], and growth in HeLa cells [30].
miR-214 and miR-199a are encoded in a region that con-
tains an E-box DNA promoter sequence [22]. A transcrip-
tion factor, Twist-1, binds to the E-box region, regulating
miR-214 and miR-199a expression [22]. The present study
showed that miR-214 expression is upregulated in a fibrosis
progression-dependent manner in the livers of patients with
chronic HCV infection and in mice with diet-induced stea-
tohepatitis (Figures 1 and 2). We previously reported an in-
crease in miR-199a in the fibrotic livers of patients with
chronic HCV infection [25], and similar findings have been
reported by others [31-33]. These data and the upregulationof Twist-1 in MCDD-induced mouse liver fibrosis (Figure 4)
suggest that Twist-1 controls the expression of the
miR-214/199a cluster in the liver. Further studies will be
needed to clarify the possible involvement of Twist-1 in
the expression of miR-214-5p in LX-2 cells.
The present study revealed that miR-214-5p overexpres-
sion in LX-2 cells significantly increased MMP-2, MMP-9,
α-SMA, and TGF-β1 mRNA expression. The overexpres-
sion of miR-199a in LX-2 cells triggers the upregulation of
tissue inhibitor of metalloproteinase (TIMP)-1, Col1a1,
and MMP-13 mRNA [34]. These results suggest that the
miR-214/199a cluster plays a primary role in stellate cell
activation. However, an understanding of the precise mo-
lecular events involved requires further research.
Conversely, the overexpression of miR-214-5p in LX-2
cells did not alter the expression of MAPK/Erk kinase 3
(MEK3), transcription factor AP-2 gamma (TFAP2C)
[29], Plenxin-B1 [30], c-Jun N-terminal kinase 1 (Jnk1)
[34], phosphatase and tensin homolog (PTEN) [35], en-
hancer of zeste homolog 2 (Ezh2) [36], and Quaking
mRNA [24], which had been reported to be targets of
miR-214 (MEK3: 0.72- to 0.77-fold, Jnk1: 1.05- to 1.20-fold,
A B
Figure 5 Effect of miR-214 overexpression on mRNA expression in LX-2 cells. (A) LX-2 cells were transfected with a miR-214 precursor or a
negative control (control) at a final concentration of 50 nM and incubated for 24 hours. miR-214 expression was quantitated using real-time PCR.
(B) The expression of fibrosis-related genes in LX-2 cells transfected with miR-214 precursors was analyzed using real-time PCR. The results are
expressed as the expression relative to that in cells transfected with the control. **P< 0.01.
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0.96-fold, TFAP2C: 0.94-fold, and Quaking: 0.88- to
1.18-fold change compared with cells transfected with
control miRNA). The PTEN 3′-UTR did not interact with
miR-214-5p in a luciferase reporter assay in LX-2 cells
(data not shown). We also found that miR-214-5p overex-










































Figure 6 Regulation of miR-214-5p expression. (A) The effect of transfo
were treated with recombinant human TGF-β1 (3 or 10 ng/ml) for 24 hour
expressed relative to miR-214 expression in cells that did not receive TGF-β
mice fed a methionine- and choline-deficient diet (MCDD). Twist-1 express
to Twist-1 expression in methionine- and choline-control diet (MCCD) mice
cells. Twist-1 expression was analyzed using real-time PCR. The results are e
**P< 0.01.migration. Therefore, the mRNA targets of miR-214-5p in
LX-2 cells are not identical to those in previous reports.
Conclusions
We report an increase in miR-214-5p in liver fibrosis in
humans and mice and the possible association of miR-





















rming growth factor (TGF)-β1 on miR-214-5p expression. LX-2 cells
s in DMEM containing 0.1% fetal bovine serum (FBS). The results are
1 treatment. *P< 0.05. (B) Twist-1 expression in the fibrotic livers of
ion was analyzed using real-time PCR. The results are expressed relative
. *P< 0.05. (C) Twist-1 expression in primary-cultured mouse stellate
xpressed relative to Twist-1 expression in cells on day 1. *P< 0.05,
Table 1 List of primers
Gene name Sequence from 5′ to 3′
Mouse GAPDH F TGCACCACCAACTGCTTAG
R GGATGCAGGGATGATGTTC
Mouse α-SMA F TCCCTGGAGAAGAGCTACGAACT
R AAGCGTTCGTTTCCAATGGT
Mouse Col1a1 F CCTGGCAAAGACGGACTCAAC
R GCTGAAGTCATAACCGCCACTG
Mouse PDGFR-β F GCGTATCTATATCTTTGTGCCAGA
R ACAGGTCCTCGGAGTCCAT
Mouse TGF-β1 F GCAACATGTGGAACTCTACCAGAA
R GACGTCAAAAGACAGCCACTC
Mouse FN1 F GATGCCGATCAGAAGTTTGG
R GGTTGTGCAGATCTCCTCGT
Mouse DDR2 F CGAAAGCTTCCAGAGTTTGC
R GCTTCACAACACCACTGCAC
Mouse ITGB1 F CAACCACAACAGCTGCTTCTAA
R TCAGCCCTCTTGAATTTTAATGT
Mouse Twist-1 F AGCTACGCCTTCTCCGTCT
R TCCTTCTCTGGAAACAATGACA
Human GAPDH F GCACCGTCAAGGCTGAGAAC
R TGGTGAAGACGCCAGTGGA
Human Col1a1 F CCCGGGTTTCAGAGACAACTTC
R TCCACATGCTTTATTCCAGCAATC
Human MMP2 F TGACATCAAGGGCATTCAGGAG
R TCTGAGCGATGCCATCAAATACA
Human TIMP1 F GGATACTTCCACAGGTCCCACAA
R CTGCAGGTAGTGATGTGCAAGAGTC
Human α-SMA F GACAATGGCTCTGGGCTCTGTAA
R CTGTGCTTCGTCACCCACGTA
Human TGF-β1 F AGCGACTCGCCAGAGTGGTTA
R GCAGTGTGTTATCCCTGCTGTCA
Human MMP9 F TCGAACTTTGACAGCGACAAGAA
R TCAGTGAAGCGGTACATAGGGTACA
α-SMA, α-smooth muscle actin; Col1a1, the type 1 collagen alpha 1 chain;
DDR, discoidin domain receptor; F, forward primer; FN, fibronectin; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; ITGB1, β1 integrin; MMP, matrix
metalloproteinase; PDGFR, platelet-derived growth factor receptor; R, reverse
primer; TIMP, tissue inhibitor of metalloproteinase; TGF, transforming growth
factor.
Iizuka et al. Fibrogenesis & Tissue Repair 2012, 5:12 Page 7 of 9
http://www.fibrogenesis.com/content/5/1/12stellate cells is regulated by TGF-β and possibly by the
transcription factor Twist-1. These results should be pur-
sued further to identify the role of miR-214-5p in liver
fibrogenesis and to develop a biomarker that reflects the




The Ethics Committee of the Osaka City University
Graduate School of Medicine approved this study(Approval No. 1358), which complied with the principles
of the Declaration of Helsinki (2008 revision). All of the
patients provided written, informed consent.
Liver biopsy specimens
Liver biopsy specimens were obtained from 35 patients
with chronic HCV (genotype 1) infection as described
previously [25]. The stage of liver fibrosis was evaluated
using the METAVIR scoring system [37]. Normal liver
tissues were taken as control samples from four patients
who underwent resection for metastatic liver tumors.
Animals
Eight- to 12-week-old male C57BL/6N mice were pur-
chased from Japan SLC, Inc. (Shizuoka, Japan). All animal
procedures were performed according to the guidelines of
the Osaka City University and Faculty of Medicine Animal
Research Committee and were approved by the committee.
The mice received either a MCDD (n=7, MP Biomedicals,
Solon, OH, USA) or a MCCD (n=7, MP Biomedicals) for
5 or 15 weeks, as previously described [26]. A similar proto-
col was followed in rats purchased from Japan SLC, Inc.
Rats received MCCD for 10 weeks, MCDD for 10 weeks,
or MCDD for 8 weeks followed by MCCD for the last 2
weeks (the last of the these being the recovery group) [26].
Cells
LX-2 cells (donated by Dr Scott Friedman [38]) and Huh7
cells were maintained in plastic culture plates in DMEM
(Sigma Chemical Co., St Louis, MO, USA) supplemented
with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad,
CA, USA). HepG2 cells (JCRB1054) were obtained from
the Health Science Research Resources Bank (Osaka,
Japan) and maintained in plastic culture plates in Minimum
Essential Medium (Invitrogen) supplemented with 10%
FBS, 1 mM sodium pyruvate (Invitrogen), and 1% non-
essential amino acids (Invitrogen). Primary hepatic stellate
cells and hepatocyte-rich and Kupffer cell-rich fractions
were prepared from mouse livers according to the previ-
ously reported method [39].
Histochemistry and immunohistochemistry
The sections were stained with 0.1% (w/v) Sirius red in a
saturated aqueous solution of picric acid (Direct Red 80;
Aldrich, Milwaukee, WI, USA) for 1 hour at room
temperature to visualize collagen fibers. Immunostaining
for α-SMA was performed as previously described [25].
Mouse liver tissue was fixed in 10% formaldehyde, em-
bedded in paraffin, and cut into 4 μm thick sections.
Quantitative real-time PCR
Gene expression was measured by real-time PCR using
cDNA, real-time PCR Master Mix Reagents (Toyobo,
Osaka, Japan), and gene-specific oligonucleotide primers
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(Applied Biosystems, Foster City, CA, USA), as previ-
ously described [25].
Transforming growth factor-β1 stimulation of LX-2 cells
LX-2 cells were seeded on 24-well plates in DMEM sup-
plemented with 10% FBS at a density of 2 × 105 cells/ml.
The cells were cultured for 14 hours, and the medium
was changed to DMEM supplemented with 0.1% FBS
plus TGF-β1 (3 or 10 ng/ml). The culture was continued
for an additional 24 hours.
Transient transfection of miRNA precursors
miR-214-5p precursors and negative control miRNA
were transfected into LX-2 cells using Lipofectamine
2000 (Invitrogen) at a final concentration of 50 nM, as
described previously [20,25]. The cells were collected after
24 hours, and total RNA was extracted.
Statistical analysis
The data shown in the bar graphs represent the means ±
SD of at least three independent experiments. Statistical
analysis was performed using the Student’s t-test. The
Jonckheere-Terpstra test was used to compare differences
between the four groups in the progressive stages of liver
fibrosis. P< 0.05 was considered statistically significant.
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